CN1056142C - Anti-cancer medicine inula helianthus-aquatica lactone - Google Patents
Anti-cancer medicine inula helianthus-aquatica lactone Download PDFInfo
- Publication number
- CN1056142C CN1056142C CN93100687A CN93100687A CN1056142C CN 1056142 C CN1056142 C CN 1056142C CN 93100687 A CN93100687 A CN 93100687A CN 93100687 A CN93100687 A CN 93100687A CN 1056142 C CN1056142 C CN 1056142C
- Authority
- CN
- China
- Prior art keywords
- lactone
- sunflower
- aquatic
- inula
- aquatica
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to anticancer medicine inula helianthus-aquatica lactone, which is a white needle-shaped crystal with a melting point of 187 to 189 DEG C, a molecular formula of C17H22O5 and molecular weight of 306. The medicine is easily dissolved in chloroform, is slightly dissolved in ethyl ether, petroleum ether and alcohol and has obvious killing effect and growth inhibiting effect on cancer cells and leukemia cells of the lung, stomach, intestine, cervix, rhinopharynx, urinary bladder, etc. of a human body. The inula helianthus-aquatica lactone provided by the present invention is novel international-initiative anticancer medicine, has the advantages of good stability, strong anticancer effect, small toxicity and clinical trial and is anticancer medicine with good development prospects.
Description
The present invention relates to a kind of is the preparation method that raw material extracts aquatic-sunflower lactone with the natural phant.
Cancer is the fiendish enemy who threatens the human life, and people are seeking effective medicine always for a long time, but do not search out good effect as yet and the little medicine of side effect so far.
The object of the present invention is to provide a kind of curative effect height, cancer therapy drug safe in utilization.
Cancer therapy drug name provided by the invention is called flower of Aquatic-sunflower Inula lactones (abbreviation compd A), and its chemical structure is:
This medicine is a kind of white, needle-shaped crystals, and fusing point 187-189 ℃, molecular formula C17H22O5 molecular weight 306 is soluble in chloroform, is dissolved in the ether of heat, in sherwood oil and the alcohol, and slightly soluble when cold.Be dissolved in alkali lye, add acid out and go out, Lei Mengde (Raymond) reagent is purple.Salt acid amide reacting positive.210nm has maximum absorption in ultraviolet.Infrared have ester and lactone and cyclopentanone absorption peak (1765,1735,1710,1670Cm
-1).HNMR reaches
13C NMR DEPT spectrum shows 17 carbon and 22 hydrogen atom signals, by three methyl (one is acyl group), four methylene radical (one of them is terminal thiazolinyl); five methynes (wherein two combine with oxygen); and five quaternary carbons (a ketone carbon, two ester carbon, an olefinic carbon) are formed.Mass spectrum has provided 306 molecular weight, and pointing out this medicine is the sesqui terpene lactones.
1, the position of ethanoyl
After hydrolysis, the hydrolyzate Aa that gets deacetylate checks not had the acetyl base peak and hydroxyl peak (3490-3380 is strong) occurred through IR figure with compound.The nucleus magnetic resonance figure of Aa and A is found that relatively σ 5.51Hd moves to σ 4.15ppm to High-Field, and appearance can be by the hydroxyl peak σ 4.71HBr of heavy water conversion.Through the test of uncoupling, when irradiation σ 5.51HD peak, simplifying appears in σ 3.05ppm peak.When irradiation 3.05 peaks, changing all appears in peaks such as σ 4.5,5.5,5.9,6.15, thereby determines that ethanoyl is positioned at the C6 position, and the terminal thiazolinyl of σ 5.9,6.15 is positioned on the lactone ring C11 position.From C6 position hydrogen peak shape be the d peak as can be known the C5 position be quaternary carbon.
2, the position of ketone group
13C NMR spectrum has provided the ketone carbon peak of σ-218.2, IR (1735Cm
-1) prompting has cyclopentanone in the molecule, therefore ketone group should be on the A ring, unimodal and coupling relation and the complexity supposition ketone group that splits branch be on the C3 position from the no 2H of hydrogen spectrum, and may be positioned on C2 or the C4, tests from uncoupling and know that the chemical shift of A ring hydrogen is all between σ 1.25-σ 2.23.When shining the methyl peak of σ 1.17, change all appears simplifying in peaks such as σ 1.5,1.7,2.3.And during the σ 5.5 of irradiation C6 position, do not have change substantially with the superiors.Compare A and approximate thing (1. chemical journal 41 (3): 254,1983 again; 2.J, arg, chem 39 (14): 2013,1974; 3.J, arg, chem 48:1356,1981:4.C.A81:63800d, 1974) carbon spectrum find that the chemical shift of compd A C5 position by low field, is σ 56.06.Show C5 except that being subjected to C8 position hydroxyl influences, neighbouring also have the group that influence is bigger.And the chemical shift of C1 position is σ 46.86, and therefore the compound displaced phase of not having a replacement with the C2 position seemingly think that ketone group is positioned at the C4 position.
3, mass spectrum, ultraviolet, infrared, it is as shown in the table for the nuclear-magnetism test data:
Table 1, ultra-violet absorption spectrum absorption peak and parsing tabulation
Compound | maximum λnm | minimum | The absorption band ownership | Remarks |
Aquatic-sunflower lactone-A | 210 | Gamma lactone | Dehydrated alcohol |
Table 2, infrared absorption spectrum absorption peak and parsing tabulation
Absorption peak wave number Cm -1 | Absorption peak strength | Group and resonance-type | Remarks |
1765 1735 1710 1670 1460 1410 1280 1252 | Strong strong and weak weak strong | The two key gamma lactone OAC of gamma lactone cyclopentanone OAC | KBr |
Table 3 hydrolyzate Aa infrared absorption spectrum absorption peak and parsing tabulation
Absorption peak wave number Cm -1 | Absorption peak strength | Group and resonance-type | Remarks |
3540——3300 1765 1730 1625 1455 1400 1260 1240 | Qiang Qiangqiang is strong | OH gamma lactone cyclopentanone | KBr |
The absorption honeybee of table 4, hydrolyzate Aa ultra-violet absorption spectrum and parsing tabulation
Compound | maximum λnm | minimum | The absorption band ownership | Remarks |
Aquatic-sunflower lactone-A | 212 | Gamma lactone | Dehydrated alcohol |
Table 5, hydrolyzate Aa's
13C nucleus magnetic resonance resolution table (400MHz heavy hydrogen pyridine)
The carbonatoms of compound | Chemical shift σ ppm | The DEPT spectrum | Relevant hydrogen atom |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 | 45.50 24.76 44.40 220 57.41 74.79 53.61 77.76 39.11 30.17 141.14 169.93 119.58 19.02 19.97 | CH CH CH CH C=O C CH CH CH CH C C CH CH CH | 1-H 2-H 2 3-H 2 T T 6-H 7-H 8-H 9-H 2 10-H T 13-H 2 14-ME 15-ME |
The proton nmr spectra resolution table instrument of table 6, compd A: Bruker-400 solvent: chloroform
Chemical shift σ ppm | Number of hydrogen atoms | Peak shape J=Hz | Remarks |
1.07 1.12 1.55 1.86 1.97 2.15 2.25 2.4 2.5 3.05 4.5 5.5 5.8 6.2 | 3H 3H 2H 1H 3H 2H 1H 1H 1H 1H 1H 1H 1H 1H | S d m m s m T dd t m m d d J=3Hz d J=3Hz | C15-H3 C14-H3 OAC C7-H C8-H C6-H C13-αH C13-βH |
The mass-spectrometric data of table 7, compd A and resolution table
Mass-to-charge ratio (m/e) | 307 | 284 | 246 | 173 | 119 | 97 | 43 |
Fragmention | m +1 | m-OAC | |||||
Remarks |
Table 8, hydrolyzate Aa mass-spectrometric data and resolution table
Mass-to-charge ratio (m/e) | 264 | 246 | ||||
Fragmention | m + | m-H2O | ||||
Remarks |
Table 9, compd A
13C nucleus magnetic resonance resolution table (400MHz chloroform)
The carbonatoms of compound | Chemical shift σ ppm | The DEPT spectrum | Relevant hydrogen atom |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 | 46.66 24.49 44.40 218.2 56.06 74.84 52.77 76.24 37.85 30.08 137.46 169.26 121.94 18.42 19.95 169.49 21.05 | CH CH2 CH2 C=O C CH CH CH CH2 CH C C=O CH2 CH3 CH3 C=O CH3 | 1-H 2-H2 3-H 6-H 7-H 8-H 9-H2 10-H 13α-H,13β-H 14-Me 15-Me 17-Me |
Table 10, hydrolyzate Aa proton nmr spectra resolution table instrument: Bruker-400 solvent: heavy hydrogen pyridine
Chemical shift σ ppm | Number of hydrogen atoms | Peak shape J=Hz | Remarks |
0.93 1.02 1.25 1.41 1.66 1.91 2.22 2.33 3.15 4.15 4.54 4.7 6.01 6.23 | 3H 3H 1H 1H 1H 1H 1H 3H 1H 1H 1H 1H 1H 1H | d s m q m m m m m α m Br α J=3Hz α J=3Hz | C15-H3 C14-H3 OAC C7-H C8-H C8-H D2O disappearance C13-α H C13-β H |
Embodiment: this compound can extract with following method: flower of Aquatic-sunflower Inula grass 1Kg (Inula helianthus Aquatica C ' Y ' Uu ex ling) is put in the apparatus,Soxhlet's, add sherwood oil (60-90 ℃) 2Kg, heat on the water-bath, refluxing extraction, there is crystallization to separate out when cold, filter,, promptly get the aquatic-sunflower lactone constituents through methyl alcohol recrystallization repeatedly, again through silica gel column layer (sample: silica gel=1: 200, the chloroform wash-out, the silica gel G thin-layer chromatography is checked (developping agent: chloroform, developer: Lei Mengde-Raymond reagent), merge same section, methanol crystallization can be got the aquatic-sunflower lactone that accounts for upper column quantity 90%, and the lactone yield can reach 3-5 ‰.
Pharmacodynamic study proves, in vitro tests: cancer cells such as people's lung, stomach, intestines, uterine neck, nasopharynx, bladder and leukemia cell are all had tangible lethal effect and growth-inhibiting effect, and ID30 is 0.1mg/kg, and ID50 is 1mg/kg, and ID90 is 4mg/kg.Recommending clinical consumption is 1mg/kg, and normal cell is not had obvious damaging action.In vivo test: to cancer in the mouse body, as ehrlich carcinoma, S180, U14, liver cancer, kinds of tumors such as carcinoma of the pancreas are all effective in cure, to ascites carcinoma curative effect P<0.01, solid carcinoma curative effect P<0.05.Administrations such as abdominal cavity, filling stomach, intramuscular injection are all effective, and effective dose iP is 30mg/kg, and im is 30mg/kg, and Po is 200mg/kg.
Safety research: toxicologic study proves, mouse LD50ip is 270mg/kg, po is 1400mg/kg, acute chronic toxicity and the long term toxicity test of rat and dog are not seen blood picture, the heart, liver, renal function and marrow, the toxic reaction of brain etc. can cause blood pressure drops for the quick intravenous injection of dog, but available metaraminol and ephedrine is prevented and treated effectively, wherein three dogs respectively repeat three tests, each one month at interval, to test dosage (in a day) at every turn and reach into dosage 10 times, off-test is for the third time put to death, core, liver, spleen, kidney, organs and tissues paraffin wax cut sections for microscopic examination such as lung, no abnormality seen changes, and result of study proves that flower of Aquatic-sunflower Inula lactones provided by the invention is the PTS of international initiative, have and have good stability, have cancer suppressing action, and toxicity is little, can try out in clinical.It is a kind of cancer therapy drug with fine DEVELOPMENT PROSPECT.
Claims (3)
1, a kind of name is called aquatic-sunflower lactone, structural formula is
The preparation method of compound, it is characterized in that may further comprise the steps:
1. be raw material with flower of Aquatic-sunflower Inula grass (Inula helianthus Aquatica C ' Y ' Uu ex ling), the flower of Aquatic-sunflower Inula grass heated with sherwood oil that service temperature is 60~90 ℃;
2. refluxing extraction has crystallization to separate out when cold;
3. filter,, promptly get the aquatic-sunflower lactone constituents with methyl alcohol recrystallization repeatedly;
4. separate through silica gel column chromatography, chloroform wash-out, silica gel G thin-layer chromatography are checked, merge same section again, and methanol crystallization obtains required product.
2, according to the process of claim 1 wherein that the 1. described flower of Aquatic-sunflower Inula grass of step and the weight ratio of sherwood oil are 1: 2.
3, according to the process of claim 1 wherein that the 4. described silica gel column chromatography of step is a sample: silica gel=1: 200.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN93100687A CN1056142C (en) | 1993-01-04 | 1993-01-04 | Anti-cancer medicine inula helianthus-aquatica lactone |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN93100687A CN1056142C (en) | 1993-01-04 | 1993-01-04 | Anti-cancer medicine inula helianthus-aquatica lactone |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 99108173 Division CN1112182C (en) | 1999-06-11 | 1999-06-11 | Medical application of aquatic-sunflower lactone |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1089945A CN1089945A (en) | 1994-07-27 |
CN1056142C true CN1056142C (en) | 2000-09-06 |
Family
ID=4983179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN93100687A Expired - Fee Related CN1056142C (en) | 1993-01-04 | 1993-01-04 | Anti-cancer medicine inula helianthus-aquatica lactone |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1056142C (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1067552C (en) * | 1994-12-06 | 2001-06-27 | 大连医科大学 | Method for extracting lipid anti-cancer medicine from liver |
CN1062866C (en) * | 1997-10-31 | 2001-03-07 | 中国人民解放军第二军医大学药学院 | Bryostatin as anti-cancer active compound |
CA2438932A1 (en) * | 2001-02-21 | 2002-09-06 | Rutgers, The State University Of New Jersey | Compositions and methods for cancer prevention and treatment derived from inula britannica |
CN101890065B (en) * | 2010-06-17 | 2013-04-17 | 昆明医科大学第一附属医院 | Inula flower injection and preparation method thereof |
CN102000066B (en) * | 2010-09-26 | 2012-07-25 | 中国科学院昆明植物研究所 | Inula helianthus-aquatica extract, anti-tumor medicament using same as active ingredient, preparation method and application thereof |
CN110563679B (en) * | 2019-08-21 | 2021-07-13 | 中山大学 | Sesquiterpene lactone compound, preparation method thereof and application of sesquiterpene lactone compound in preparation of medicine for preventing and treating nasopharyngeal carcinoma |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5549369A (en) * | 1978-10-04 | 1980-04-09 | Nippon Kayaku Co Ltd | Antitumorigenic substance |
EP0098041A2 (en) * | 1982-05-19 | 1984-01-11 | R.P. Scherer Corporation | Sesquiterpene lactones, extracts containing them, their preparation and pharmaceutical use |
JPS617201A (en) * | 1984-06-20 | 1986-01-13 | Sumitomo Chem Co Ltd | Fungicide |
-
1993
- 1993-01-04 CN CN93100687A patent/CN1056142C/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5549369A (en) * | 1978-10-04 | 1980-04-09 | Nippon Kayaku Co Ltd | Antitumorigenic substance |
EP0098041A2 (en) * | 1982-05-19 | 1984-01-11 | R.P. Scherer Corporation | Sesquiterpene lactones, extracts containing them, their preparation and pharmaceutical use |
JPS617201A (en) * | 1984-06-20 | 1986-01-13 | Sumitomo Chem Co Ltd | Fungicide |
Non-Patent Citations (3)
Title |
---|
C.A.VOL.106,NO.15 1987.4.3 OVEZDUTDYEV,A.ET AL "THE STRUCTURE OF ERGOLIDE";C.A.VOL.112,NO.15 1990.3.26 RUSTAIYAN A.ET AL A SECO-GUAIANOLIDE AND OTHER SESQUITERPENE LACTONE FROM POSTIA BOBYCINA" * |
C.A.VOL.106,NO.15 1987.4.3 OVEZDUTDYEV,A.ET AL "THE STRUCTURE OF ERGOLIDE" * |
C.A.VOL.112,NO.15 1990.3.26 RUSTAIYAN A.ET AL A SECO-GUAIANOLIDE AND OTHER SESQUITERPENE LACTONE FROM POSTIA BOBYCINA" * |
Also Published As
Publication number | Publication date |
---|---|
CN1089945A (en) | 1994-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FUJITA et al. | Fungal metabolites. Part 12. Potent immunosuppressant, 14-deoxomyriogin,(2s, 3r, 4r-(e) 2-amino-3, 4-dihydroxy-2-hydroxymethyleicos-6-enoic acid and structure-activity relationships of myriocin derivatives | |
EP2223929A1 (en) | Gambogic glycoside derivatives and analogs, the preparation and the application thereof | |
Lei et al. | Synthesis and anti-tumor activity of 14-O-derivatives of natural oridonin | |
CN1056142C (en) | Anti-cancer medicine inula helianthus-aquatica lactone | |
WO2012033266A1 (en) | Novel artemisinin or deoxoartemisinin-glycolipid hybrid derivatives and antiangiogenic use thereof | |
Hatano et al. | Tannins of Coriaria japonica A. Gray. I.: Coriariins A and B, new dimeric and monomeric hydrolyzable tannins | |
CN101613388A (en) | The coumarin kind compound of glucuronidation and application thereof | |
Wong et al. | Isolation, structural elucidation, and chemical synthesis of 2-hydroxy-3-octadecyl-5-methoxy-1, 4-benzoquinone (irisoquin), a cytotoxic constituent of Iris missouriensis | |
CN1112182C (en) | Medical application of aquatic-sunflower lactone | |
CN110903241B (en) | Separation and purification method of water-soluble catechol tetrahydroisoquinoline alkaloid | |
EP2486026B1 (en) | Derivatives of di(phenylpropanoid) glycerol for the treatment of cancer | |
EP2520580B1 (en) | Halogenated dideoxy saccharide derivatives, preparation method and use thereof | |
CN109206469B (en) | Glycyrrhetinic acid derivative and preparation method and application thereof | |
Hatano et al. | Camptothins A and B: New Dimeric Hydrolyzable Tannins from Camptotheca acuminata DECNE. | |
FI98889C (en) | A method for preparing an antineoplastic drug derived from a plant extract | |
LIN et al. | Tannins and related compounds. XCVIII.: Structures of three new dimeric ellagitannins, excoecarianin and excoecarinins A and B, isolated from the leaves of Excoecaria kawakamii Hayata | |
Liu et al. | Dihydromyricetin from Ampelopsis grossedentata and its derivatives: Structural characterization and anti-hepatocellular carcinoma activity | |
Oliveira et al. | Design, synthesis, and antitumor evaluation of novel anthraquinone derivatives | |
CN108752404B (en) | A kind of berberine salt derivative and its preparation method and application that triazole is sugar-modified | |
Ohmoto et al. | Constituents of Hibiscus moscheutos L. I | |
CN114149400B (en) | Preparation and application of gentisic acid mixed source hetero-terpenoid compound in sarcandra glabra | |
CN115010773B (en) | Eugenol glycosyl thiourea derivative, preparation method and application thereof | |
CN110003291B (en) | Fluoro glycosyl modified taxol compound and synthesis method and application thereof | |
CN114644673A (en) | Estradiol derivative, preparation method and medical application thereof | |
Cui et al. | Sulfoglycolipid from the marine brown alga Sargassum Hemiphyllum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20000906 Termination date: 20110104 |